In a recent update from UBS, analyst Ashwani Verma maintains a "Buy" rating for United Therapeutics (UTHR, Financial). However, the price target for UTHR has been revised downward from $410.00 to $385.00 USD. This adjustment reflects a -6.10% change from the previous target.
Despite the lowered price target, the "Buy" recommendation indicates continued confidence in United Therapeutics' market performance. Investors will be watching closely to see how (UTHR, Financial) navigates the market environment following this update.
These changes, effective June 30, 2025, highlight a strategic reassessment by UBS while still suggesting potential value in United Therapeutics stock. As always, market participants should consider various factors when making investment decisions regarding (UTHR, Financial).
Wall Street Analysts Forecast
Based on the one-year price targets offered by 12 analysts, the average target price for United Therapeutics Corp (UTHR, Financial) is $384.77 with a high estimate of $510.00 and a low estimate of $314.00. The average target implies an upside of 33.81% from the current price of $287.54. More detailed estimate data can be found on the United Therapeutics Corp (UTHR) Forecast page.
Based on the consensus recommendation from 14 brokerage firms, United Therapeutics Corp's (UTHR, Financial) average brokerage recommendation is currently 2.1, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for United Therapeutics Corp (UTHR, Financial) in one year is $395.07, suggesting a upside of 37.4% from the current price of $287.54. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the United Therapeutics Corp (UTHR) Summary page.
